1-phenethylpyrrolidin-3-ol | 79278-81-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-phenethylpyrrolidin-3-ol
• 英文别名: 1-(2-phenylethyl)pyrrolidin-3-ol
• CAS: 79278-81-2
• 化学式: C₁₂H₁₇NO
• 分子量: 191.273
• InChiKey: RIYQNVRAUWHVNR-UHFFFAOYSA-N

物化性质

• 熔点：
  30-35 °C
• 沸点：
  145 °C(Press: 2 Torr)
• 密度：
  1.092±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-phenethylpyrrolidin-3-ol 在 草酰氯 、 三乙胺 作用下， 以 二氯甲烷 、 二甲基亚砜 为溶剂， 生成 1-phenethyl-pyrrolidin-3-one
  参考文献：
  名称：

  Identification of a novel class of succinyl-nitrile-based Cathepsin S inhibitors

  摘要：

  The synthesis and in vitro activities of a series of suceinyl-nitrile-based inhibitors of Cathepsin S are described. Several members of this class show nanomolar inhibition of the target enzyme as well as cellular potency. The inhibitors displaying the greatest potency contain N-alkyl substituted piperidine and pyrrolidine rings spiro-fused to the alpha-carbon of the P1 residue. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.02.046
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 lithium aluminium tetrahydride 、 乙醚 作用下， 生成 1-phenethylpyrrolidin-3-ol
  参考文献：
  名称：

  A Study of Some 2,3-Dioxopyrrolidines and Derived Bipyrrolidines¹

  摘要：

  DOI：

  10.1021/jo01116a009

文献信息

• Penem derivatives and antimicrobial agents containing the same
  申请人：SUNTORY LIMITED

  公开号：EP0774465A1

  公开（公告）日：1997-05-21

  Penem derivatives represented by the following Formula (I): wherein Z represents a hydroxyl group or a fluorine atom, R1 represents a substituted or unsubstituted alkyl, alkenyl, aralkyl group, aryl group, heterocyclic, or acyl group, or a hydrogen atom, and R2 represents a hydrogen atom or a carboxyl-protecting group; and pharmacologically acceptable salts thereof are antibacterial agents effective against, inter alia, methicillin-resistant Staphylococcus aureus. The derivatives and salts are novel except when R1 is ethyl and Z is hydroxyl. The analogous compounds in which R2 is a carboxyl-protecting group and any hydroxyl group represented by Z is protected are novel process intermediates.

  Penem衍生物由以下公式（I）表示：其中Z代表一个羟基团或氟原子，R1代表一个取代或未取代的烷基，烯基，芳基甲基，芳基，杂环基或酰基，或氢原子，R2代表一个氢原子或羧基保护基；及其药理学上可接受的盐是有效的抗菌剂，可用于治疗耐甲氧西林金黄色葡萄球菌等感染。这些衍生物和盐是新颖的，除非R1是乙基且Z是羟基。其中R2是羧基保护基且Z代表的任何羟基被保护的类似化合物是新颖的工艺中间体。
• Synthesis, Structure–Activity Relationships, and Antiviral Profiling of 1-Heteroaryl-2-Alkoxyphenyl Analogs as Inhibitors of SARS-CoV-2 Replication
  作者：Dorothée Bardiot、Laura Vangeel、Mohamed Koukni、Philippe Arzel、Marleen Zwaagstra、Heyrhyoung Lyoo、Patrick Wanningen、Shamshad Ahmad、Linlin Zhang、Xinyuanyuan Sun、Adrien Delpal、Cecilia Eydoux、Jean-Claude Guillemot、Eveline Lescrinier、Hugo Klaassen、Pieter Leyssen、Dirk Jochmans、Karolien Castermans、Rolf Hilgenfeld、Colin Robinson、Etienne Decroly、Bruno Canard、Eric J. Snijder、Martijn J. van Hemert、Frank van Kuppeveld、Patrick Chaltin、Johan Neyts、Steven De Jonghe、Arnaud Marchand

  DOI：10.3390/molecules27031052

  日期：——

  compound library against SARS-CoV-2, yielding a 1-heteroaryl-2-alkoxyphenyl analog as a promising hit. Antiviral profiling revealed this compound was active against various beta-coronaviruses and preliminary mode-of-action experiments demonstrated that it interfered with viral entry. A systematic structure–activity relationship (SAR) study demonstrated that a 3- or 4-pyridyl moiety on the oxadiazole moiety

  严重急性呼吸系统综合症冠状病毒 2 (SARS-CoV-2) 是 COVID-19 的病原体，已导致大流行，这仍然是一个巨大的公共卫生负担。尽管有疫苗可用，但仍然需要小分子抗病毒药物。为了确定可用于随后的命中到先导优化活动的新型和类似药物的命中物质，我们对 160 K 化合物库针对 SARS-CoV-2 进行了高通量筛选，产生了 1-杂芳基-2-烷氧基苯基类似物是一个很有前途的目标。抗病毒分析显示该化合物对各种β-冠状病毒具有活性，初步作用模式实验表明它干扰了病毒进入。系统的构效关系 (SAR) 研究表明，恶二唑部分上的 3-或 4-吡啶基部分是最佳的，而恶二唑可以被各种其他杂芳环取代。此外，烷氧基允许一些结构多样性。
• Pyrrolidinium derivatives
  申请人：Prat Quinones Maria

  公开号：US20050282875A1

  公开（公告）日：2005-12-22

  New pyrrolidinium derivatives having the chemical structure of general formula (I) are disclosed; as well as processes for their preparation, pharmaceutical compositions comprising them and their use in therapy as antagonists of M3 muscarinic receptors.

  本发明公开了具有一般式(I)化学结构的新吡咯烷衍生物，以及它们的制备过程、包含它们的药物组合物和它们作为M3肌动蛋白受体拮抗剂在治疗中的使用。
• Penem derivatives and antimicrobial agent containing the same
  申请人：Ishiguro Masaji

  公开号：US20050004092A1

  公开（公告）日：2005-01-06

  A penem derivative represented by the following formula (I): wherein R 1 represents a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted alkylthio group, a substituted or unsubstituted alkenylthio group, a substituted or unsubstituted aralkylthio group, a substituted or unsubstituted arylthio group, a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted heterocyclic thio group, a substituted or unsubstituted acylthio group, a mercapto group or a hydrogen atom, and R 2 represents a hydrogen atom or a carboxyl-protecting group; or a pharmacologically acceptable salt thereof. The compound (I) exhibits strong antibacterial activities, and especially, shows strong activities against MRSA. It is therefore useful not only as a general antibacterial agent but also as an antibacterial agent for MRSA against which no general antibacterial agents are recognized to be-effective.

  以下是公式（I）所代表的一种青霉烷衍生物： 其中，R1代表取代或未取代的烷基、取代或未取代的烯基、取代或未取代的芳基烷基、取代或未取代的芳基、取代或未取代的烷基硫基、取代或未取代的烯基硫基、取代或未取代的芳基烷基硫基、取代或未取代的芳基硫基、取代或未取代的杂环基、取代或未取代的杂环硫基、取代或未取代的酰基硫基、巯基或氢原子，R2代表氢原子或羧酸保护基；或其药学上可接受的盐。该化合物（I）表现出强大的抗菌活性，特别是对MRSA表现出强大的活性。因此，它不仅有用作一般抗菌剂，还有用作抗MRSA的抗菌剂，对于这种细菌，一般的抗菌剂被认为无效。
• New pyrrolidinium derivatives
  申请人：Quinones Prat Maria

  公开号：US20070129420A1

  公开（公告）日：2007-06-07

  New pyrrolidinium derivatives having the chemical structure of general formula (I) are disclosed; as well as processes for their preparation, pharmaceutical compositions comprising them and their use in therapy as antagonists of M3 muscarinic receptors.

  本发明揭示了具有一般式(I)化学结构的新吡咯烷衍生物；以及它们的制备方法、包含它们的制药组合物以及它们作为M3肌动蛋白受体拮抗剂在治疗中的应用。